Recordati takeover bid gains a new backer, shares anchored to CVC offer price

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 15:58.

Recordati (IT0003828271) is again in focus on Euronext Milan after an updated takeover structure. Belgian investor GBL has joined CVC in a reinforced €10.7 billion bid that aims to take the Italian pharma group private, according to recent specialist press coverage. Pharmaphorum report on the Recordati bid

What the new bid structure shows

CVC already controls around 46.8 percent of Recordati’s capital and now fronts a broader consortium of funds together with GBL, which has formally backed a public offer at €51.29 per share, valuing the equity at approximately €10.7 billion. Deal details in Pharmaphorum The consortium’s earlier interest had been signaled at roughly €52 per share, implying a slightly higher valuation near €10.9 billion.

Recordati’s shares in Milan have recently traded close to the offer range, with London’s secondary quote around €51.40 on 12 May 2026, underlining that the market has largely priced in the bid expectations. Investing.com price summary for Recordati The company has said the tender process is expected to close before year-end, which would remove Recordati from the Euronext Milan listing if the bid succeeds.

Analyst views and sector context on Friday

The takeover narrative plays out against a broader European pharma sector that includes peers such as Sanofi and Novartis, where deal-making and portfolio refocusing remain recurring themes. Analysts at Intermonte, cited by Italian business daily Il Sole 24 Ore and relayed by sector commentary, have expressed scepticism that the delisting will proceed under current terms, arguing that the €51.29 per share offer does not seem particularly compelling for Recordati’s minority investors. Intermonte assessment quoted by Pharmaphorum

In this environment, European equity markets on Friday have been described as muted, with London’s FTSE indices slipping amid pressure on commodity names and ongoing uncertainty around AI-related stocks, according to Reuters market coverage. Reuters overview of European equity markets Against that backdrop, a largely predefined corporate action such as Recordati’s takeover frame can act as an anchor for the shares, limiting short-term volatility and aligning the trading range tightly with the bid price.

The products behind Recordati’s revenue

Recordati generates its revenue from prescription pharmaceuticals with a mix of specialty and primary care products, and a growing focus on rare diseases. A representative product portfolio includes cardiovascular drugs, urology treatments and rare-disease therapies, such as formulations for conditions like hyperammonemia and other metabolic disorders, distributed mainly across Europe and selected international markets. Recordati Investor Relations product overview

Where the Recordati shares trade today

Recordati shares (IT0003828271) trade on Euronext Milan, with recent indications around the €51 mark in secondary listings, broadly aligned with the €51.29 per share takeover offer as of 2026-05-12 based on London price data in euros. Latest London-quoted price snapshot for Recordati

Disclaimer: This article is for information purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Data and estimates are based on sources cited in the text and may change over time.